Nasdaq

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION

IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...
Nasdaq

Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair

IRVINE, Calif., May 18, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...
EurekAlert!

Novel TEER repair device meets primary endpoint in treating degenerative mitral regurgitation in patients not eligible for surgery

BOSTON – September 17, 2022 – Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral ...
Seeking Alpha

CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION

SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...

Edwards’ Heart Valve Clips Targeted by Cardiovalve Patent Suit

Edwards Lifesciences Corp.’s catheter-based heart valve clips infringe a patent for a prosthetic support used to repair leaky ...
Hosted on MSN

Edwards Lifesciences’ PASCAL System: A Promising Trial in Heart Valve Repair

Edwards Lifesciences Corp. ((EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is currently conducting a pivotal clinical trial titled ‘Edwards PASCAL Transcatheter ...
Medscape

PASCAL Mitral Valve Repair Shines at 2 Years in CLASP

Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.
MD&M East

Edwards Makes Gains in Tricuspid Regurgitation Repair with CE Mark

The Irvine, CA-based company said the Pascal repair system demonstrated high procedural success and significant clinical improvements in patients with challenging tricuspid anatomy and severe TR.
BioWorld

Edwards receives CE mark for Pascal tricuspid repair to compete with Abbott’s Triclip

Edwards Lifesciences Corp. has gained a CE mark for its Pascal transcatheter valve repair system to treat tricuspid regurgitation (TR). It was previously approved for mitral regurgitation treatment.
TCTMD

First Commercial Multicenter Experience With the PASCAL Transcatheter Valve Repair System for Tricuspid Regurgitation

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below: Receive the the latest news, research, and ...
TCTMD

TCT ID 2: The PASCAL Transcatheter Valve Repair System for the Treatment of Tricuspid Regurgitation – Day Outcomes From the CLASP TR Early Feasibility Study

TCT 059: Meta-Analysis of Bleeding, MACE and Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After PCI Receive the the latest news, research, and presentations from major ...